TP53 and colorectal carcinoma: An impaired cross talk between mutant p53 and its apoptotic target genes with no transactivation and enhanced tumorigenic properties such as survival, proliferation, angiogenesis, and chemoresistance has been reported to contribute to CRC disease progression (9, 10).